Pomerantz Law Firm Investigates Regeneron Pharmaceuticals for Investor Claims and Securities Fraud

Investigation of Regeneron Pharmaceuticals

The Pomerantz Law Firm has initiated an investigation concerning allegations involving Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). This inquiry is focused on claims from investors, specifically to assess if Regeneron, along with certain executives and board members, partook in any form of securities fraud or other unlawful practices that may have harmed shareholders.

On May 15, 2026, Regeneron revealed through a press release that the outcome of a Phase 3 clinical trial, which tested the effectiveness of two dosage levels of fianlimab—a LAG-3 inhibitor—in combination with cemiplimab (PD-1 inhibitor), did not achieve statistical significance for the primary goal of improving progression-free survival (PFS). This news was particularly significant because it compared the new treatment against pembrolizumab, another type of PD-1 inhibitor used in melanoma therapy.

As a direct result of the release, which detailed these disappointing findings regarding the efficacy of the trial, Regeneron's stock price witnessed a steep decline, plummeting by $68.57 per share, equivalent to a 9.82% drop, and closing at $629.68 on May 16, 2026. This drastic fall has raised considerable concerns among investors who now question the integrity of the disclosed information leading up to the trial results.

Pomerantz LLP, a well-known law firm with offices spread across major cities including New York, Chicago, and London, specializes in corporate and securities class actions. With a legacy that stems from the pioneering work of Abraham L. Pomerantz, regarded as the dean of the class action bar, the firm has a long-standing reputation for advocating on behalf of investors impacted by securities fraud and related corporate malfeasance. Over its 85-year history, Pomerantz has secured numerous multimillion-dollar restitution awards for victims of fiduciary breaches and misconduct.

Given the substantial drop in stock value and the serious nature of the claims being investigated, investors who believe they have experienced losses due to Regeneron's actions are advised to reach out to Pomerantz LLP. Interested parties can contact Danielle Peyton via email at [email protected] or by phone at 646-581-9980, ext. 7980, for more information on how to join the investigation and possibly participate in a class action lawsuit.

The ongoing scrutiny surrounding Regeneron is a reminder of the broader implications of comprehensive and honest disclosures in the pharmaceuticals sector, where investment trust hinges on the expectations of clinical efficacy and safety as communicated to shareholders. This situation not only affects individual investors but also resonates throughout the market as confidence wavers amid allegations of fraud or negligence by public companies.

For further details on Pomerantz LLP and their efforts in investor protection through legal recourse, visit their official website at www.pomlaw.com. Their commitment to safeguarding shareholder interests in the turbulent landscape of securities trading and corporate responsibility underscores the crucial role of legal advocacy in corporate governance and accountability.